FDA Clearance Tracker · P240021
Atellica IM Total PSA II (tPSAII)
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 3, 2025
Approved
Time to decision
531 days
Received Jun 20, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P240021
- Device name
- Atellica IM Total PSA II (tPSAII)
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- Tarrytown, NY
- Received
- Jun 20, 2024
- Decided
- Dec 3, 2025
- Decision
- Approved
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica IM Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MTF. The earliest in FDA's data is P850048, decided Feb 25, 1986.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.